PSMA-targeted imaging is appealing, given the inadequate sensitivity of conventional imaging technologies for low-volume PCa lesions and thus their suboptimal performance for detection of early biochemically recurrent prostate cancer (BRPC) and occult metastatic PCa. This evidence concerns the gene FOLH1 and prostate cancer.